The number of inclusion was reached normally

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

Inclusion Criteria:

• Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease
• Measurable disease
• Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry

Exclusion Criteria:

• Prior chemotherapy for metastatic disease
• HER2 positive and/or hormonal receptor positive